ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Zhen-Ao Presents Breakthrough Findings on Nucleotide-Based Anti-Aging Research at the Heidelberg Forum

By: Get News

The 2025 Heidelberg International Life Sciences Forum, jointly organized by the China-Europe Science and Technology Innovation Cooperation Center (CESTICC) and the German-Chinese Association for Life Sciences and Cultural Development (DCLC), concluded on October 25 in the German city, which is renowned for its scientific heritage.

The annual event brought together leading figures in global life sciences, including Nobel laureates, academicians, and distinguished researchers from around the world. The forum focused on frontier topics such as microscopy, quantum materials, neuroscience, precision medicine, and artificial intelligence, serving as a significant platform for international scientific exchange.

At this year’s forum, Zhen-Ao Group, a biotechnology company from China, gained recognition for its latest research in the field of anti-aging. The company received the Nucleotide R&D Technology Award, presented by Professor Stefan Hell, the 2014 Nobel Laureate in Chemistry, in acknowledgment of Zhen-Ao’s long-standing contributions to nucleotide-based biomedical research.

One of the key highlights of the forum was a presentation by Dr. John Wu, Foreign Member of the Russian Academy of Engineering, Vice President for Academic Affairs of Zhengzhou University of Technology, and a renowned expert in immunocytology. Representing Zhen-Ao Group as an invited speaker, Dr. Wu introduced the results of a human clinical study on the anti-aging effects of nucleotides. The randomized, double-blind, controlled trial included 121 participants aged 60-70 and followed international research standards. After 19 weeks of exogenous nucleotide supplementation, participants showed a mean reduction of 3.08 years in DNA methylation age, suggesting a potential biological rejuvenation effect.

The findings provide empirical evidence supporting the role of nucleotides in modulating biological aging and contribute to the growing body of research in precision medicine. The study drew significant interest from attending experts and was regarded as one of the forum’s most notable scientific contributions.

Dr. Wu also engaged in in-depth discussions with attending scientists regarding the role of 5’-nucleotidases (5’-NTs) as biological regulators, receiving broad recognition for the team’s three decades of research in nucleotide science.

Presenting the award, Professor Stefan Hell commended the research for advancing scientific understanding of health and aging through innovative approaches.

A representative from Zhen-Ao Group stated that the recognition at the Heidelberg Forum marks an important milestone in the company’s international research collaboration. Looking ahead, Zhen-Ao plans to continue advancing anti-aging studies through global partnerships and scientific innovation, contributing to the development of evidence-based health solutions worldwide.

Media Contact
Company Name: ZHEN-AO GROUP CO.,LTD.
Contact Person: Zitian Geng
Email: Send Email
State: Dalian
Country: China
Website: https://www.zhen-ao.com/

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.